Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioventus Inc. - Class A Common Stock (NQ:BVS)

6.980 +0.050 (+0.72%)
Streaming Delayed Price Updated: 3:25 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,832
Open 6.900
Bid (Size) 6.970 (2)
Ask (Size) 6.990 (8)
Prev. Close 6.930
Today's Range 6.855 - 7.045
52wk Range 5.280 - 14.38
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Earnings Scheduled For May 6, 2025
Via Benzinga

Performance

YTD
-34.3%
-34.3%
1 Month
-6.9%
-6.9%
3 Month
-32.8%
-32.8%
6 Month
-38.0%
-38.0%
1 Year
+12.0%
+12.0%

More News

Read More
Examining the Future: Bioventus's Earnings Outlook
Via Benzinga
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
From Bioventus, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gapping stocks in Tuesday's session
Via Chartmill
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
Via Benzinga
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500 Gains 1%; Vimeo Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
Via Benzinga
Bioventus Reports Third Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
From Bioventus, Inc.
Via GlobeNewswire
Solventum Stock Earns 81 RS Rating
Via Investor's Business Daily
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
Executives Buying W. P. Carey And 2 Other Stocks
Via Benzinga
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
BVS Stock Earnings: Bioventus Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace

Frequently Asked Questions

Is Bioventus Inc. - Class A Common Stock publicly traded?
Yes, Bioventus Inc. - Class A Common Stock is publicly traded.
What exchange does Bioventus Inc. - Class A Common Stock trade on?
Bioventus Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bioventus Inc. - Class A Common Stock?
The ticker symbol for Bioventus Inc. - Class A Common Stock is BVS on the Nasdaq Stock Market
What is the current price of Bioventus Inc. - Class A Common Stock?
The current price of Bioventus Inc. - Class A Common Stock is 6.980
When was Bioventus Inc. - Class A Common Stock last traded?
The last trade of Bioventus Inc. - Class A Common Stock was at 05/20/25 03:25 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.